Have any questions? 706-721-6582 or cts@augusta.edu
- Gilead GS-US-200-4334: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV
Clinical Trial
Gilead GS-US-200-4334: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV
This study will look at a new, first-in-class anti-HIV drug called GS-6207. It will see how effective and tolerable it is in treating people with HIV.
Eligibility Criteria
- INCLUSION: 1. Adults age 18 years or older who are HIV positive and have not previously taken HIV drugs 2. HIV count at least 200, CD4 cell count at least 200 EXCLUSION: 1. No history of medical conditions not allowed by the study 2. No use of medications not allowed by the study 3. No lab values outside of the ranges acceptable for the study
RESEARCH. INNOVATION. DISCOVERY.